Article
5-fluorouracil Synergized with Raloxifene and Cytosine β-D-arabinofuranoside to Combat Colorectal Cancers in vitro via Controlling Lipolysis
2016-12-15
Abstract excerpt
Background: Colorectal cancers (CRCs) are the 3rd leading mortality cause in the states. Raloxifene (RX) was recently approved for cancer prevention. Therefore, 5-flurouracil (FU), a DNA blocker, stimulates apoptotic cascade in CRC cells. Unfortunately, many of the therapies that use FU and RX are likely to become ineffective due to drug resistance. Therefore, providing cytosine-$-D-arabinoside (CYT), an S-phase s...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 583e002a-7958-5f1d-80c5-e983539fda6a
- DOI
- 10.3923/jpt.2017.14.23
